STOCK TITAN

Catalyst Pharmaceutical (CPRX) Form 4 Filings

CPRX

Here are the Form 4 insider transactions from Catalyst Pharmaceutical Inc. (CPRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A Form 4 covers the transactions officers, directors and large holders report, so if you follow CPRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CPRX filings page.

Rhea-AI Summary

Catalyst Pharmaceuticals Chief Legal Officer Brian Elsbernd reported the cancellation of his equity interests in connection with the acquisition of Catalyst by Angelini Pharma S.p.A. On July 15, 2026, 242,501 common shares were disposed of at $31.50 per share, and all reported RSUs and stock options were cancelled and converted into cash rights using a $31.50 per share amount in the payout formulas. Following these transactions, the filing lists zero remaining holdings of the reported securities.

Rhea-AI Summary

CATALYST PHARMACEUTICALS director Daniel J. Curran reported dispositions of equity awards to the issuer in connection with the consummation of a Merger. On 2026-07-15, 5,468 restricted stock units and stock options over 18,115 and 40,000 shares of common stock were cancelled. Each restricted stock unit represented a contingent right to receive one share, and each award was converted into a right to receive a cash payment based on a $31.50 per-share merger price, less the applicable option exercise prices. All reported options and RSUs vested in full at closing, and these derivative positions now show zero shares following the transactions.

Rhea-AI Summary

Catalyst Pharmaceuticals director David S. Tierney reported the disposition of 383,314 shares of common stock at $31.50 per share to the issuer on July 15, 2026, in connection with the acquisition by Angelini Pharma S.p.A. All reported RSUs and fully vested stock options were cancelled at closing and converted into cash based on the $31.50 merger price, leaving no reported remaining holdings of these securities.

Rhea-AI Summary

Steve Miller, chief operating and scientific officer of Catalyst Pharmaceuticals, reported the disposition to the issuer of 1,093,803 shares of common stock at $31.50 per share on July 15, 2026, in connection with the acquisition of Catalyst by Angelini Pharma S.p.A. (the Merger).

On the same date, all reported restricted stock units (47,826; 16,534; 11,873 underlying shares) and multiple option grants (including 158,454 options at $22.77, 202,958 at $21.12 and 275,000 at $3.42) were canceled and converted into rights to receive cash based on a $31.50 reference price per share. Each option and RSU vested in full at consummation of the Merger, and reported holdings after these transactions were 0 shares and 0 derivative securities.

Rhea-AI Summary

Catalyst Pharmaceuticals director Tamar Thompson reported the disposition of all reported equity positions in connection with the acquisition of Catalyst Pharmaceuticals, Inc. by Angelini Pharma S.p.A. On 2026-07-15, 3,773 shares of common stock were surrendered at $31.50 per share, and multiple restricted stock unit and stock option awards covering specified shares were cancelled and converted into cash based on the $31.50 per-share merger price. Following these transactions, the reported holdings show 0 shares and 0 derivative awards remaining for the positions covered.

Rhea-AI Summary

CATALYST PHARMACEUTICALS, INC. Chief HR Officer Gregg Russo disposed of equity in connection with the acquisition by Angelini Pharma S.p.A. at $31.50 per share. The report shows the return of 476 common shares plus multiple RSUs and stock options to the issuer for cash consideration. After these transactions, no holdings in the reported securities remain.

Rhea-AI Summary

Patrick J. McEnany, chairman of Catalyst Pharmaceuticals, reported the disposition of 4,171,559 shares of common stock at $31.50 per share in connection with the acquisition of Catalyst by Angelini Pharma S.p.A., and this Form 4 shows 0 shares of common stock held directly afterward.

The reported restricted stock units and stock options covering additional shares were cancelled at merger closing and converted into rights to receive cash payments based on a $31.50 per-share value, with each award vesting in full at consummation.

Rhea-AI Summary

CATALYST PHARMACEUTICALS, INC. director Donald A. Denkhaus reported disposing of 498,773 shares of common stock at $31.50 per share on July 15, 2026, in a disposition to the issuer completed in connection with the acquisition of Catalyst by Angelini Pharma S.p.A. (the Merger).

On the same date, all reported restricted stock units and stock options, covering additional shares of common stock, were cancelled and converted into rights to receive cash payments based on the $31.50 per-share merger consideration, and his reported holdings in these securities fell to 0.

Rhea-AI Summary

Catalyst Pharmaceuticals Chief Commercial Officer Jeffrey Del Carmen reported issuer dispositions on July 15, 2026, in connection with the acquisition of Catalyst by Angelini Pharma S.p.A. He disposed of 14,337 common shares at $31.5000 per share, and all reported restricted stock units and stock options vested in full, were canceled, and converted into rights to receive cash payments calculated using a $31.50 per-share merger price. Following these transactions, he reports no remaining Catalyst equity holdings, including common stock, RSUs, or stock options.

Rhea-AI Summary

Catalyst Pharmaceuticals Chief Strategy Officer Preethi Sundaram reported dispositions tied to the company’s acquisition by Angelini Pharma S.p.A. On July 15, 2026 she disposed of 54,804 shares of common stock at $31.50 per share, and all reported RSUs and stock options were canceled and converted into cash rights, leaving her with no reported common or derivative holdings.

Rhea-AI Summary

Catalyst Pharmaceuticals President and CEO Richard J. Daly reported the disposition of 271,266 shares of common stock at $31.50 per share on July 15, 2026, in connection with the acquisition of Catalyst by Angelini Pharma S.p.A.

All reported restricted stock units and stock options were cancelled and converted into cash rights based on the $31.50 merger price, with option payouts equal to the merger price minus the exercise price per share. After these transactions, no holdings of the reported awards remain.

Rhea-AI Summary

CATALYST PHARMACEUTICALS, INC. reports that Chief Medical Officer William T. Andrews disposed of 2,309 common shares at $31.50 per share in a transaction with the issuer, in connection with the acquisition by Angelini Pharma S.p.A. (the Merger).

On the same date, all of his reported RSUs (29,776 and 12,209 units) and stock options (98,652 at a $22.77 exercise price and 124,447 at $24.90) vested, were cancelled, and converted into cash rights based on the $31.50 merger price, leaving no reported remaining holdings in these awards.

Rhea-AI Summary

CATALYST PHARMACEUTICALS director Molly Harper reported the disposition to the issuer of 3,694 common shares at $31.50 per share on July 15, 2026, in connection with the acquisition of the company by Angelini Pharma S.p.A. In the same merger-related event, she also disposed of multiple restricted stock units and stock options, which were cancelled and converted into cash rights calculated using the $31.50 merger price, leaving the reported positions at zero.

Rhea-AI Summary

Catalyst Pharmaceuticals chief financial officer Michael Wayne Kalb reported dispositions of common stock, restricted stock units and stock options on July 15, 2026, in connection with the acquisition of Catalyst by Angelini Pharma S.p.A. The reported awards vested in full, were cancelled, and converted into rights to receive cash based on a price of $31.50 per share or, for options, the excess of $31.50 over each option’s exercise price, leaving the reported positions at zero.

Rhea-AI Summary

Catalyst Pharmaceuticals Chief Medical Officer William T. Andrews reported routine equity compensation activity involving restricted stock units that convert into common stock. On June 3, 2026, 3,052 restricted stock units were exercised into 3,052 shares of common stock at a conversion price of $0.0000 per share.

Of these, 743 shares were withheld by Catalyst Pharmaceuticals to cover applicable tax obligations, described as a tax-withholding disposition. After this withholding, Andrews directly holds 2,309 shares of common stock. Footnotes explain that each restricted stock unit represents a right to receive one common share upon vesting and that the related derivative securities vest in five equal annual tranches on June 2 of each year from 2026 through 2030.

Rhea-AI Summary

Catalyst Pharmaceuticals Chief HR Officer Gregg Russo reported equity compensation activity. On February 17, 2026, 687 restricted stock units vested and converted into an equal number of common shares at $0.00 per share. Of these, 211 shares were withheld to cover taxes, leaving 476 shares delivered. The derivative award vests in five equal annual tranches each February 13 from 2026 through 2030, with shares required to be delivered within sixty days of vesting.

Rhea-AI Summary

Catalyst Pharmaceuticals President and CEO Richard J. Daly reported equity compensation activity. On January 5, 2026, 42,105 restricted stock units vested and were converted into an equal number of Catalyst common shares at a price of $0 per share. According to the filing, this award vests in five equal annual tranches from January 1, 2025 through January 1, 2029.

To cover withholding taxes tied to the vesting, the company withheld 10,577 common shares, leaving Daly with 271,266 common shares directly owned after the transactions. He also reported 2,618,539 restricted stock units beneficially owned following this vesting event.

Rhea-AI Summary

Catalyst Pharmaceuticals director Molly Harper reported exercising stock options and selling common shares of the company. On 12/12/2025, she exercised options to purchase 20,000 shares of common stock at an exercise price of $5.78 per share, converting them into common shares. She then sold common stock in several open-market transactions, including 15,527 shares at a weighted average price of $23.198, 4,473 shares at $23.734, and 6,746 shares at $23.06 per share. Following these transactions, she directly beneficially owned 2,360 shares of common stock and 128,497 options to purchase common stock. The sales were made on the open market for personal reasons and to help fund the option exercise, and were not due to any disagreement with the company.

Rhea-AI Summary

Catalyst Pharmaceuticals, Inc. (CPRX) chairman of the board and director Patrick J. McEnany reported stock gifts to family trusts. On 12/01/2025, he made bona-fide gifts of common stock, par value $0.001 per share, recorded at a price of $0 per share, classified under transaction code "G" for gifts. After the reported transactions, he directly beneficially owned 4,148,477 shares of Catalyst Pharmaceuticals common stock. The explanation notes that the gifts were to irrevocable trusts for family members who do not share his household, and he is not a trustee and has no direct or indirect influence over the trusts' investment decisions.